SBC Medical Group (NASDAQ:SBC) Stock Rating Upgraded by Wall Street Zen

SBC Medical Group (NASDAQ:SBC - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Saturday.

Several other equities analysts have also issued reports on the company. Weiss Ratings lowered SBC Medical Group from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, May 22nd. BTIG Research reissued a "buy" rating and set a $8.00 price objective on shares of SBC Medical Group in a research report on Thursday. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $8.50.

Get Our Latest Research Report on SBC

SBC Medical Group Stock Performance

SBC Medical Group stock opened at $3.66 on Friday. SBC Medical Group has a twelve month low of $2.78 and a twelve month high of $5.07. The company has a quick ratio of 3.78, a current ratio of 3.82 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $375.44 million, a P/E ratio of 7.79 and a beta of 0.59. The stock's 50 day moving average is $3.08 and its 200 day moving average is $3.56.

SBC Medical Group (NASDAQ:SBC - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported $0.10 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.12 by ($0.02). SBC Medical Group had a net margin of 27.99% and a return on equity of 18.81%. The company had revenue of $49.19 million for the quarter, compared to analysts' expectations of $45.37 million. On average, equities research analysts predict that SBC Medical Group will post 0.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SBC Medical Group

Several large investors have recently bought and sold shares of SBC. BlackRock Inc. bought a new position in SBC Medical Group during the 2nd quarter valued at about $2,846,000. Geode Capital Management LLC bought a new stake in shares of SBC Medical Group in the second quarter worth approximately $455,000. Segall Bryant & Hamill LLC purchased a new position in shares of SBC Medical Group during the first quarter valued at approximately $340,000. Millennium Management LLC purchased a new position in shares of SBC Medical Group during the third quarter valued at approximately $219,000. Finally, Bank of New York Mellon Corp bought a new position in SBC Medical Group during the second quarter valued at approximately $83,000. 60.82% of the stock is currently owned by institutional investors.

Key Headlines Impacting SBC Medical Group

Here are the key news stories impacting SBC Medical Group this week:

• Positive Sentiment: Strong second-quarter growth: SBC reported revenue of $49.19 million, up 13% year over year and ahead of the $45.37 million analyst estimate. Net income jumped 335%, while adjusted EBITDA increased 32%, indicating improved profitability following the company’s restructuring. SBC Medical Group Holdings Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Ambitious clinic expansion: Management outlined a goal of reaching 1,000 clinics by 2035 and identified as much as $15 million in potential annual fee revenue. The targets support the company’s long-term growth narrative and could improve recurring revenue if executed successfully. SBC targets 1,000 clinics by 2035 while outlining $15M annual fee upside
• Positive Sentiment: Analyst confidence: BTIG Research reaffirmed its “buy” rating and set an $8.00 price target, implying substantial upside from the recent trading level. BTIG Research rating information
• Neutral Sentiment: Key earnings caveat: Quarterly EPS was $0.10, below the $0.12 consensus estimate. However, the revenue beat and sharp increases in net income and EBITDA may be receiving greater attention from investors.
• Negative Sentiment: Execution risk remains: The 1,000-clinic objective extends through 2035, so achieving the projected fee opportunity will depend on sustained expansion, successful integration and continued profitability improvements. SBC Q2 2026 earnings call transcript

SBC Medical Group Company Profile

(Get Free Report)

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company's primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.

Read More

• Five stocks we like better than SBC Medical Group
• Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
• Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
• NVIDIA's $500 Billion GPU Financing Deal Fuels Path Toward $270
• Sandisk’s Margins Look Like Software. Can They Last?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in SBC Medical Group Right Now?

Before you consider SBC Medical Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SBC Medical Group wasn't on the list.

While SBC Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here